000 02164cam  2200385zi 4500
0019.866809
003CaOODSP
00520221107162138
006m     o  d f      
007cr cn|||||||||
008190108e201911  onc     o    f000 0 eng d
020 |a9780660235646
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH13-9/13-2019E-PDF
24500|aGuidance document : |bfees for the right to sell drugs.
24630|aFees for the right to sell drugs
264 1|aOttawa, Ontario : |bHealth Canada = Santé Canada, |cNovember 2019.
264 4|c©2019
300 |a1 online resource (11 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Ligne directrice : frais à payer pour le droit de vendre un médicament.
500 |a"Pub.: 180725."
500 |aIssued also in HTML format.
520 |a"Once a drug is authorized for sale in Canada, industry must pay an annual fee to retain the right to sell the drug in Canada. Health Canada has charged fees since 1995 in order to recover some of the associated costs with post-market regulatory activities such as assessing safety signals and trends and communicating about risks. This document provides guidance on how fees for the right to sell drugs will be administered in accordance with the Food and Drugs Act and as stipulated in the Fees in Respect of Drugs and Medical Devices Order and the Regulations Amending and Repealing Certain Regulations Made under the Financial Administration Act"--Introduction, page 6.
650 0|aDrug approval|zCanada.
650 0|aFees, Administrative|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLigne directrice : |w(CaOODSP)9.866810
795 |tGuidance document |w(CaOODSP)9.856866
85640|qPDF|s232 KB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H13-9-13-2019-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fees/right-to-sell-drugs-2019/document.html